Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
Teresa Helsten, Maria Schwaederlé, Razelle Kurzrock
Cancer and Metastasis Reviews (2015) Vol. 34, Iss. 3, pp. 479-496
Open Access | Times Cited: 121

Showing 26-50 of 121 citing articles:

Targeting Tyrosine kinases in Renal Cell Carcinoma: “New Bullets against Old Guys”
Teresa Alonso‐Gordoa, Laura García‐Bermejo, Enrique Grande, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 8, pp. 1901-1901
Open Access | Times Cited: 49
Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis
Jinglin Zhang, Patrick Ming‐Kuen Tang, Yuhang Zhou, et al.
Cells (2019) Vol. 8, Iss. 6, pp. 637-637
Open Access | Times Cited: 46
The paradox of cancer genes in non-malignant conditions: implications for precision medicine
Jacob J. Adashek, Shumei Kato, Scott M. Lippman, et al.
Genome Medicine (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 46
Role of thyroid hormones in craniofacial development
Victoria D. Leitch, J. H. Duncan Bassett, Graham R. Williams
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 3, pp. 147-164
Closed Access | Times Cited: 41
Biological Significance and Targeting of the FGFR Axis in Cancer
Athina‐Myrto Chioni, Richard Grose
Cancers (2021) Vol. 13, Iss. 22, pp. 5681-5681
Open Access | Times Cited: 40
Serine protease PRSS23 drives gastric cancer by enhancing tumor associated macrophage infiltration via FGF2
Shanshan Qin, Zidi Wang, Congcong Huang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 24
FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?
Csongor György Lengyel, Sadaqat Hussain, Andreas Seeber, et al.
Life (2022) Vol. 12, Iss. 1, pp. 81-81
Open Access | Times Cited: 23
A comprehensive review on the indazole based derivatives as targeted anticancer agents
Sachin Puri, Siddhi Sawant, Kapil Juvale
Journal of Molecular Structure (2023) Vol. 1284, pp. 135327-135327
Closed Access | Times Cited: 15
A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug
Chen Chen, Sujata Maiti Choudhury, Darawalee Wangsa, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 45
Muenke syndrome: An international multicenter natural history study
Paul Kruszka, Yonit A. Addissie, Colin M. P. Yarnell, et al.
American Journal of Medical Genetics Part A (2016) Vol. 170, Iss. 4, pp. 918-929
Closed Access | Times Cited: 44
Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer
Navid Sobhani, Anna Ianza, Alberto D’Angelo, et al.
Cells (2018) Vol. 7, Iss. 7, pp. 76-76
Open Access | Times Cited: 42
MiR‐16‐1‐3p and miR‐16‐2‐3p possess strong tumor suppressive and antimetastatic properties in osteosarcoma
Vadim Maximov, Rania Akkawi, Saleh Khawaled, et al.
International Journal of Cancer (2019) Vol. 145, Iss. 11, pp. 3052-3063
Open Access | Times Cited: 40
Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer
Katarzyna Starska, Ewa Forma, Iwona Lewy‐Trenda, et al.
Cellular Oncology (2018) Vol. 41, Iss. 3, pp. 253-268
Closed Access | Times Cited: 39
Anti-Cancer Effect of Cordycepin on FGF9-Induced Testicular Tumorigenesis
Ming‐Min Chang, Siou-Ying Hong, Shang‐Hsun Yang, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 8336-8336
Open Access | Times Cited: 33
The Present and Future of Neoadjuvant and Adjuvant Therapy for Locally Advanced Gastric Cancer
Anna Koerner, Ryan H. Moy, Sandra Ryeom, et al.
Cancers (2023) Vol. 15, Iss. 16, pp. 4114-4114
Open Access | Times Cited: 11
Fibroblast growth factor receptors in breast cancer
Shuwei Wang, Zhongyang Ding
Tumor Biology (2017) Vol. 39, Iss. 5, pp. 101042831769837-101042831769837
Open Access | Times Cited: 38
Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia
Francesca Musumeci, Chiara Greco, Giancarlo Grossi, et al.
Cancers (2018) Vol. 10, Iss. 11, pp. 430-430
Open Access | Times Cited: 34
Targeting the FGF/FGFR axis and its co-alteration allies
Yuji Uehara, Sadakatsu Ikeda, K.H. Kim, et al.
ESMO Open (2022) Vol. 7, Iss. 6, pp. 100647-100647
Open Access | Times Cited: 19
Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond
In‐Ho Kim
Journal of the Korean Gastric Cancer Association (2023) Vol. 24, Iss. 1, pp. 29-29
Open Access | Times Cited: 10
Current Landscape of Molecular Biomarkers in Gastroesophageal Tumors and Potential Strategies for Co-Expression Patterns
M. Korpan, Hannah Christina Puhr, J.M. Berger, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 340-340
Open Access
New derivatives based on zerumbone scaffold as anticancer inhibitors: Synthesis, in vitro anticancer evaluation, docking, and MD simulation studies
Ngoc Hung Truong, Lê Minh Hà, H. T. Luu, et al.
Journal of Chemical Research (2025) Vol. 49, Iss. 1
Open Access
Ameloblastic Fibro-Odontoma with an FGFR1 Mutation: A Case Report
Oumaima Aouam, Nard G. Janssen, Wendy W.J. de Leng, et al.
Head and Neck Pathology (2025) Vol. 19, Iss. 1
Open Access
Immediate Autologous Breast Reconstruction in a Patient With Achondroplasia
Josephine A. D’Abbondanza, Esta S. Bovill, Sheina A. Macadam
Annals of Plastic Surgery (2025)
Closed Access
FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and α-Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1
K. Świderska, Anna Szlachcic, Łukasz Opaliński, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 7, pp. 2098-2098
Open Access | Times Cited: 28
The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor
Rafael Morales‐Barrera, Cristina Suárez, Macarena González, et al.
Cancer Treatment Reviews (2020) Vol. 86, pp. 102000-102000
Closed Access | Times Cited: 26

Scroll to top